scholarly journals Vaginal metastasis of bladder urothelial carcinoma: Description of a case and revision of literature

2017 ◽  
Vol 89 (2) ◽  
pp. 156 ◽  
Author(s):  
Carmelo A. Di Franco ◽  
Daniele Porru ◽  
Giovanni Giliberto ◽  
Alessandra Viglio ◽  
Bruno Rovereto
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Radical Cystectomy ◽  
Vaginal Bleeding ◽  
Urothelial Cancer ◽  
Vaginal Wall ◽  
Rare Entity ◽  
Bladder Urothelial Carcinoma ◽  
Vaginal Metastasis ◽  
History Of

Vaginal metastases from urothelial cancer are a rare entity and in literature, few cases are described. We report a case of a 68 year-old woman with history of bladder urothelial carcinoma underwent to radical cystectomy who came in our department after 5 months for pelvic pain and vaginal bleeding. Objective examination revealed an ulcerative, solid vaginal lesion in the upper vaginal wall. We performed a vaginal biopsy that showed urothelial carcinoma compatible with the primitive bladder cancer. The patient underwent to surgery and was sent to oncological evaluation.

scholarly journals Unexpected Bladder Urothelial Carcinoma in a Young Adult-Case Report with Literature Review

2020 ◽  
pp. 1-3
Author(s):  
Hamdy Aboutaleb ◽  
Hamdy Aboutaleb
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Lateral Wall ◽  
Complete Removal ◽  
Heavy Smoking ◽  
Urothelial Bladder Carcinoma ◽  
Bladder Urothelial Carcinoma ◽  
Urothelial Bladder ◽  
History Of ◽  
Children And Young Adults

Background: Bladder cancer is the third most common malignancy in adults, accounting for 2.1% of all cancer-related deaths. Its highest incidence is in the 6th decade of life. Urothelial bladder cancer is rare in children and adolescents, presenting in only 0.003% of the population under 20 years of age. The aim of the paper is to report a rare case of bladder urothelial carcinoma in a young girl aged 27 years. Case Presentation: We report the case of a 27-year-old girl who presented with painless gross hematuria. She had a history of heavy smoking and recurrent cystitis. CT-KUB revealed polypoidal tumor in right lateral wall of the urinary bladder. Transurethral resection of the tumor was performed for complete removal of the tumor. Follow-up revealed no recurrence for two years. Conclusion: Urothelial bladder carcinoma should be excluded in children and young adults when they present with painless hematuria. Although this presentation is rare, its prognosis is good.

scholarly journals Prolonged survival in a patient with choroidal metastases from urothelial bladder cancer

2013 ◽  
Vol 3 (4) ◽  
pp. 36 ◽  
Author(s):  
Kirsty L. Wiltshire ◽  
Norman Laperriere ◽  
Robert G. Bristow
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Urothelial Cancer ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder ◽  
History Of ◽  
Carcinoma Of The Bladder ◽  
Disease Free ◽  
New Onset

Choroidal metastases secondary to urothelial carcinoma areextremely rare and are usually associated with an extremely poorprognosis. We present a case of an 88-year-old man with newlydiagnosed urothelial carcinoma of the bladder who presented withacute loss of vision before commencing definitive concurrentchemoradiotherapy to the bladder. Ophthalmological examinationdemonstrated bilateral choroidal metastases. He received palliativeradiotherapy to the orbits and completed his planned radiotherapyto the bladder. He remained disease-free at last follow-up 4 yearsafter the completion of treatment. We review the literature particularlywith regard to diagnosis and management of choroidalmetastases. Choroidal metastases should be considered in a patientwith a history of urothelial cancer presenting with new onset ofeye symptoms.

scholarly journals Network Pharmacology-Based Study on the Active Component and Mechanism of the Anti-Non-Invasive and Invasive Bladder Urothelial Carcinoma Effects of Zhuling Jisheng Decoction

2021 ◽  
Vol 2021 ◽  
pp. 1-21
Author(s):  
Chenyu Ma ◽  
Jianlong Wang ◽  
Na Zhao ◽  
Zhenya Pan ◽  
Yi Lu ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Oral Bioavailability ◽  
Urothelial Cancer ◽  
Target Genes ◽  
Network Pharmacology ◽  
Cancer Resistance ◽  
Bladder Urothelial Carcinoma ◽  
Urothelial Bladder ◽  
The Impact

Zhuling Jisheng decoction is employed for the treatment of bladder urothelial cancer in clinical practice of traditional Chinese medicine. However, there are few studies on its precise mechanism. For the antibladder cancer action of Zhuling Jisheng decoction, a network pharmacological technique was used to design a component/target/pathway molecular regulatory network. The TCMSP dataset was used to identify the chemical makeup of Zhuling Jisheng decoction, which was then analyzed and assessed for oral bioavailability and pharmacological similarity. The chemical composition of Zhuling Jisheng decoction was identified through the TCMSP database, and it was evaluated and screened based on oral bioavailability and drug similarity. The GEO database was searched for genes associated with urothelial bladder carcinoma, and gene targets associated with bladder urothelial cancer resistance were chosen by comparison. The function and linked pathways of the target genes were examined and screened using annotation, visualization, and a comprehensive discovery database. The impact of Zhuling Jisheng decoction on urothelial bladder cancer was studied using Cytoscape software to create a component/target/pathway network. Finally, 69 and 55 target genes were discovered for noninvasive bladder urothelial cancer and invasive bladder urothelial cancer, respectively. In noninvasive urothelial cancer, 118 pathways were highly enriched, including the TNF signaling pathway and the IL-17 signaling route. 103 pathways were highly enriched in invasive urothelial cancer, including the p53 signaling route, bladder cancer route, and calcium signaling route. There were 18 and 15 drug targets associated with noninvasive and invasive bladder urothelial carcinoma prognoses. Many signaling pathways directly act on tumours, and indirect pathways inhibit the development of bladder urothelial carcinoma. This research establishes a scientific foundation for further research into the framework of action of Zhuling Jisheng decoction in the therapy of bladder urothelial cancer.

1233: Natural History of Bladder Cancer in Patients with P0 Disease at Radical Cystectomy

2006 ◽  
Vol 175 (4S) ◽  
pp. 397-397 ◽  
Author(s):  
Wassim Kassouf ◽  
Philippe E. Spiess ◽  
Gordon A. Brown ◽  
Mark F. Munsell ◽  
H. Barton Grossman ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Natural History ◽  
Radical Cystectomy ◽  
History Of

scholarly journals A Case of Primary Small-Cell Carcinoma of the Bladder

2016 ◽  
Vol 9 (3) ◽  
pp. 574-579 ◽  
Author(s):  
Ashita Ono ◽  
Yosuke Hirasawa ◽  
Mitsumasa Yamashina ◽  
Naoto Kaburagi ◽  
Takashi Mima ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Radical Cystectomy ◽  
Small Cell Carcinoma ◽  
Distant Metastasis ◽  
Small Cell ◽  
Common Type ◽  
Cell Of Origin ◽  
Carcinoma Of The Bladder

Primary small-cell carcinoma arising from the bladder (SmCCB) is uncommon. It differs from urothelial carcinoma (UC), the most common type of bladder cancer, with respect to its cell of origin, biology, and prognosis. Biologically, prostatic SmCCB is much more aggressive than UC, and the prognosis for cases with distant metastasis is especially poor. We report here a case of primary SmCCB (cT3bN1M0) treated with radical cystectomy.

Is Robot-assisted Radical Cystectomy the Preferred Minimal Invasive Procedure for Non-advanced Bladder Urothelial Carcinoma(T1-T2N0M0)? A Single Center Retrospective Study.

2020 ◽  
Author(s):  
Ming Xiao ◽  
Zhaohui Zhong ◽  
Jiannan Ren ◽  
Wei Xiong
Keyword(s):  
Urothelial Carcinoma ◽  
Radical Cystectomy ◽  
Operation Time ◽  
Invasive Procedure ◽  
Minimal Invasive ◽  
Postoperative Treatment ◽  
Transfusion Rate ◽  
Robot Assisted ◽  
Bladder Urothelial Carcinoma ◽  
Hospitalization Costs

Abstract Background: To investigate the perioperative efficacy and cost of robot-assisted radical cystectomy(RARC) and laparoscopic RC(LRC) in patients with non-advanced bladder urothelial carcinomaMethods: 156 patients with non-advanced bladder urothelial carcinoma undergoing minimally invasive radical cystectomy in our center between January 2015 and April 2020 were included. Perioperative data and hospitalization expenses were extracted from our database. All analyses were performed using SPSS 23.0 software, and p < 0.05 was considered statistically significant.Results: The proportion of male patients was 86.5%(135/156) and the median age was 65(IQR 59-71) years old. RARC had a lower PSM rate (0 vs 5.3%,P=0.051), longer median operation time(370 vs 305 min,P<0.001) and higher median hospitalization cost(20565.2 vs 15532.4$,P<0.001). There were no significant differences in intraoperative transfusion rate, anesthesia resuscitation in ICU, postoperative hospital stay, 30-d complications and postoperative treatment expenses between the two groups(P=0.815,0.715, 0.817,0.92 and 0.543,respectively.)Conclusion: Short operation time and low hospitalization costs are favorable factors for LRC, but RARC may be the preferred surgical procedure for non-advanced bladder urothelial carcinoma considering the potentially low PSM rate.Trial registration: A complete informed consent was obtained from the patient and their families before the surgery.Informed consent was signed for all patients.This study was approved by the Ethics Review Committee of the Second Xiangya Hospital of Central South University

scholarly journals Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort

2012 ◽  
Vol 6 (6) ◽  
pp. 217 ◽  
Author(s):  
Nicholas E. Power ◽  
Wassim Kassouf ◽  
David Bell ◽  
Armen Aprikian ◽  
Yves Fradet ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Neoadjuvant Chemotherapy ◽  
Natural History ◽  
Radical Cystectomy ◽  
Node Positive ◽  
Number Of Patients ◽  
History Of ◽  
Modern Era

Background: The present study documents the natural history and outcomes of high-risk bladder cancer after radical cystectomy (RC) in patients who did not receive neoadjuvant chemotherapy during a contemporary time period.Methods: We analyzed 1180 patients from 1993 to 2008 with >pT3N0 or pT0-4N+ bladder cancer who underwent RC ± standard (sLND) or extended (eLND) lymph node dissection from 8 Canadian centres.Results: Of the 1180 patients, 55% (n = 643) underwent sLND, 34% (n = 402) underwent ePLND and 11% did not undergo a formal LND. Of the total number of patients, 321 (27%) received adjuvant chemotherapy. The median follow-up was 2.1 years (range: 0.6 to 12.9). Overall 30-day mortality was 3.2%. Clinical and pathological stages T3-4 were present in 6.1% and 86.7% of the patients, respectively; this demonstrates a dramatic understaging. Overall survival (OS) at 2 and 5 years was 60% and 43%, respectively. Patients who received adjuvant chemotherapy hada 2- and 5-year disease-specific survival (DSS) of 72% and 57% versus 64% and 51% for those who did not (log-rank p = 0.0039). The 2- and 5-year OS for high-risk node-negative disease was 67%and 52%, respectively, whereas for node-positive patients, the OS was 52% and 32%, respectively (p < 0.001). The OS, DSS and RFS for patients with pN0 were significantly improved compared to those who did not undergo a LND (log-rank p = 0.0035, 0.0241 and 0.0383, respectively).Interpretation: This series suggests that bladder cancer outcomes inadvanced disease have improved in the modern era. The need for improved staging investigations, use of neoadjuvant chemotherapyand performance of complete LND is emphasized.

scholarly journals Re-operation within 30 days of radical cystectomy: Identifying high-risk patients and complications using ACS-NSQIP database

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Rashid K. Sayyid ◽  
Diana Magee ◽  
Amanda E. Hird ◽  
Benjamin T. Harper ◽  
Eric Webb ◽  
...  
Keyword(s):  
Risk Factors ◽  
Bladder Cancer ◽  
African American ◽  
High Risk ◽  
Radical Cystectomy ◽  
High Risk Patients ◽  
Metastatic Bladder Cancer ◽  
Risk Patients ◽  
History Of ◽  
African American Race

Introduction: Radical cystectomy (RC) is a highly morbid procedure, with 30-day complication rates approaching 31%. Our objective was to determine risk factors for re-operation within 30 days following a RC for non-metastatic bladder cancer. Methods: We included all patients who underwent a RC for non-metastatic bladder cancer using The American College of Surgeons National Surgical Quality Improvement Program database between January 1, 2007 and December 31, 2014. Logistic regression analyses were used to evaluate predictors of re-operation. Results: A total of 2608 patients were included; 5.8% of patients underwent re-operation within 30 days. On multivariable analysis, increasing body mass index (BMI) (odds ratio [OR] 1.04; 95% confidence interval [CI] 1.01–1.07), African-American race (vs. Caucasian OR 2.29; 95% CI 1.21–4.34), and history of chronic obstructive pulmonary disease (COPD) (OR 2.33; 95% CI 1.45–3.74) were significant predictors of re-operation within 30 days of RC. Urinary diversion type (ileal conduit vs. continent) and history of chemotherapy or radiotherapy within 30 days prior to RC were not. Patients who underwent re-operation within this timeframe had a significantly higher mortality rate (4.0% vs. 1.6%) and were more likely to experience cardiac (7.2% vs. 1.9%), pulmonary (23.0% vs. 3.0%), neurological (2.0% vs. 0.49%), and venous thromboembolic events (10.5% vs. 5.4%), as well as infectious complications (64.5% vs. 24.1%) with a significantly longer hospital length of stay (16.5 vs. 7.0 days). Conclusions: Recognizing increasing BMI, COPD, and African-American race as risk factors for re-operation within 30 days of RC will allow urologists to preoperatively identify such high-risk patients and prompt them to adopt more aggressive approaches to minimize postoperative surgical complications.

scholarly journals Vulvar Metastasis from Bladder Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-3
Author(s):  
Fouad Aoun ◽  
Elie El Rassy ◽  
Hampig Raphael Kourie ◽  
Eric Hawaux ◽  
Roland van Velthoven
Keyword(s):  
Bladder Cancer ◽  
Urothelial Carcinoma ◽  
English Literature ◽  
Rare Entity ◽  
Pathological Characteristics ◽  
Carcinoma Of The Bladder

Vulvar metastasis of urothelial carcinoma of the bladder is a very rare entity; few cases are reported in the English literature. In this paper, we describe the clinical and pathological characteristics, evolution, and treatment of a patient with vulvar metastasis of urothelial carcinoma of the bladder followed by a brief review of the reported cases in the literature.

Sign in / Sign up

Export Citation Format

Share Document